On July 14, 3SBio fell 5.49% in regular trading, trading at 17.06 HKD/share, with turnover of 184 million HKD.
Within the Biotechnology sector where 3SBio belongs, the overall sector trended weak. Among individual stocks, Innovent Bio down 0.51%, BeiGene down 0.86%, Akeso down 1.73%, SKB Bio down 2.06%, RemeGen down 3.43%.
3SBio Inc is an investment holding company principally engaged in the development, production, marketing and sale of biopharmaceutical products. Its major products include TPIAO, EPIAO, YISAIPU and other biologics, as well as CDMO services. The company's products are mainly used in chemotherapy-induced thrombocytopenia, chronic kidney disease anemia, ankylosing spondylitis and psoriasis, with operations in both domestic and overseas markets.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments